SURPASS-EARLY two-year results favor starting tirzepatide early in type 2 diabetes

Adults in the first few years after a type 2 diabetes diagnosis had bigger drops in blood sugar and weight over two years when treated with tirzepatide than with intensified conventional care, according to results from the SURPASS-EARLY trial ^[1]. Tirzepatide is the molecule sold as Mounjaro for type 2 diabetes and as Zepbound for weight management.

SURPASS-EARLY was a randomized, open-label, parallel-group phase 4 trial run at 78 sites in 10 countries (ClinicalTrials.gov: NCT05433584) ^[1]. It enrolled 794 adults who had a type 2 diabetes history of at most four years and whose blood sugar was not adequately controlled with diet, exercise and metformin ^[1]. Participants were assigned to tirzepatide at 15 mg or the maximum tolerated dose, or to intensified conventional care — treatment used in clinical practice and supported by local treatment guidelines, which could include other GLP-1 receptor agonists but not tirzepatide ^[1].

What the numbers showed

The main goal was to show that tirzepatide was no worse than intensified conventional care for change in HbA1c from the start of the study to two years ^[1]. It cleared that bar and went further, meeting the secondary goals of superiority for HbA1c, weight and waist circumference ^[1].

HbA1c fell by an average of 1.99 percentage points with tirzepatide (95% CI, -2.12 to -1.87) compared with 1.32 percentage points with intensified conventional care (95% CI, -1.44 to -1.19) ^[1]. That is an estimated treatment difference of 0.68 percentage points in favor of tirzepatide (95% CI, -0.84 to -0.51; P < 0.001) ^[1].

Weight loss favored tirzepatide by an estimated 8.0 kg — about 17.6 pounds — with a confidence interval running from 9.39 kg to 6.50 kg (P < 0.001) ^[1]. Waist circumference shrank by an estimated 6.2 cm more with tirzepatide (95% CI, -7.54 to -4.93 cm; P < 0.001) ^[1]. These figures come from what the researchers called the treatment regimen estimand, an analysis approach that counts participants according to their assigned group ^[1].

The most striking difference was in how many people reached normal blood sugar. An HbA1c under 5.7% — the level generally considered non-diabetic — was reached by 60.2% of the tirzepatide group versus 24.0% of the intensified conventional care group ^[1].

The most common side effects in both groups were gastrointestinal ^[1]. The abstract does not break out how often nausea, vomiting or diarrhea occurred, or how many people stopped treatment, so those details are not yet known from this source.

Why it matters for patients

Most type 2 diabetes care in the United States follows a stepwise pattern: start with metformin and lifestyle changes, then add other drugs as blood sugar creeps up. SURPASS-EARLY was designed to test whether moving to tirzepatide soon after diagnosis produces better and more durable control than that conventional approach ^[1]. Over two years, it did, on all three measures the trial set out to test ^[1].

The comparison group matters here. This was not tirzepatide versus placebo or versus metformin alone. Intensified conventional care could include other GLP-1 receptor agonists — a category that includes semaglutide — and still reduced HbA1c by 1.32 percentage points ^[1]. The 0.68-point gap and the 8.0 kg weight gap are on top of an already active comparator ^[1].

There are real limits. The trial was open-label, meaning participants and investigators knew which treatment was assigned, which the authors list as the study's limitation ^[1]. Eli Lilly, which makes tirzepatide, was the primary funding source ^[1]. The abstract also does not report whether the differences translated into fewer heart attacks, strokes, kidney problems or eye complications — two years is a short window for those outcomes, and they were not among the stated objectives ^[1].

It is also not known from these results what happens after treatment stops. Reaching an HbA1c under 5.7% on medication is not the same as remission, and the abstract does not describe any period off drug ^[1].

What happens next

The two-year results were published in June 2026 ^[1]. Whether professional guidelines shift toward earlier use of tirzepatide in newly diagnosed type 2 diabetes, and how US insurers respond, is not addressed in this publication. Any longer follow-up from SURPASS-EARLY has not been reported in this source.